← board
NRSNW
distress 7/10 · high distress / dilution risk$0.06-26%today-71% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
0%
Price & events
-71.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-26.0%
1D
-39.9%
1W
-71.1%
1M
-71.1%
3M
—
6M
—
1Y
—
2Y
—
5Y
-71.1%
All
Overview
- Market Cap
- $1.96M
- Volume
- 203
- 52 Week Range
- $0.06 – $0.21
- Total Shares
- 32.56M
- Float Shares
- 23.34M
- RVOL
- 7.06x
- Beta
- 1.56
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.